<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39463836</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2374-7943</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>ACS central science</Title><ISOAbbreviation>ACS Cent Sci</ISOAbbreviation></Journal><ArticleTitle>Engineering a SARS-CoV-2 Vaccine Targeting the Receptor-Binding Domain Cryptic-Face via Immunofocusing.</ArticleTitle><Pagination><StartPage>1871</StartPage><EndPage>1884</EndPage><MedlinePgn>1871-1884</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acscentsci.4c00722</ELocationID><Abstract><AbstractText>The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is the main target of neutralizing antibodies. Although they are infrequently elicited during infection or vaccination, antibodies that bind to the conformation-specific cryptic face of the RBD display remarkable breadth of binding and neutralization across <i>Sarbecoviruses</i>. Here, we employed the immunofocusing technique PMD (protect, modify, deprotect) to create RBD immunogens (PMD-RBD) specifically designed to focus the antibody response toward the cryptic-face epitope recognized by the broadly neutralizing antibody S2X259. Immunization with PMD-RBD antigens induced robust binding titers and broad neutralizing activity against homologous and heterologous <i>Sarbecovirus</i> strains. A serum-depletion assay provided direct evidence that PMD successfully skewed the polyclonal antibody response toward the cryptic face of the RBD. Our work demonstrates the ability of PMD to overcome immunodominance and refocus humoral immunity, with implications for the development of broader and more resilient vaccines against current and emerging viruses with pandemic potential.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruun</LastName><ForeName>Theodora U J</ForeName><Initials>TUJ</Initials><Identifier Source="ORCID">0000-0002-7462-2537</Identifier><AffiliationInfo><Affiliation>Sarafan ChEM-H, Stanford University, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sarafan ChEM-H, Stanford University, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidenbacher</LastName><ForeName>Payton A-B</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Sarafan ChEM-H, Stanford University, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Stanford University, Stanford, California 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utz</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sarafan ChEM-H, Stanford University, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Biophysics Program, Stanford University School of Medicine, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Medical Scientist Training Program, Stanford University School of Medicine, Stanford, California 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><Identifier Source="ORCID">0000-0001-6503-4541</Identifier><AffiliationInfo><Affiliation>Sarafan ChEM-H, Stanford University, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chan Zuckerberg Biohub, San Francisco, California 94158, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Cent Sci</MedlineTA><NlmUniqueID>101660035</NlmUniqueID><ISSNLinking>2374-7943</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare the following competing financial interest(s): P.A.-B.W. and P.S.K. are named as inventors on patent applications applied for by Stanford University and the Chan Zuckerberg Biohub on epitope restriction for antibody selection.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39463836</ArticleId><ArticleId IdType="pmc">PMC11503491</ArticleId><ArticleId IdType="doi">10.1021/acscentsci.4c00722</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kalinke U.; et al. Clinical development and approval of COVID-19 vaccines. Expert Rev. Vaccines 2022, 21, 609–619. 10.1080/14760584.2022.2042257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2042257</ArticleId><ArticleId IdType="pmc">PMC8935460</ArticleId><ArticleId IdType="pubmed">35157542</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E. E.; et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 2020, 383, 2439–2450. 10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F. P.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S.; et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022, 602, 654–656. 10.1038/s41586-021-04387-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04387-1</ArticleId><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C. Q.; Vishwanath S.; Carnell G. W.; Chan A. C. Y.; Heeney J. L. Immune imprinting and next-generation coronavirus vaccines. Nat. Microbiol. 2023, 8, 1971–1985. 10.1038/s41564-023-01505-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-023-01505-9</ArticleId><ArticleId IdType="pubmed">37932355</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinardi J. R.; Srivastava A. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines 2023, 11, 370.10.3390/biomedicines11020370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020370</ArticleId><ArticleId IdType="pmc">PMC9953148</ArticleId><ArticleId IdType="pubmed">36830907</ArticleId></ArticleIdList></Reference><Reference><Citation>Menachery V. D.; et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015, 21, 1508–1513. 10.1038/nm.3985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3985</ArticleId><ArticleId IdType="pmc">PMC4797993</ArticleId><ArticleId IdType="pubmed">26552008</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M.; Marzi A.; Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020, 5, 562–569. 10.1038/s41564-020-0688-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0688-y</ArticleId><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Musunuri S.; Weidenbacher P. A. B.; Kim P. S. Bringing immunofocusing into focus. Npj Vaccines 2024, 9, 1–11. 10.1038/s41541-023-00792-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00792-x</ArticleId><ArticleId IdType="pmc">PMC10776678</ArticleId><ArticleId IdType="pubmed">38195562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.; et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 2023, 23, 189–199. 10.1038/s41577-022-00784-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen J. E.; et al. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Sci. Immunol. 2022, 7, eadf1421.10.1126/sciimmunol.adf1421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.adf1421</ArticleId><ArticleId IdType="pmc">PMC9765460</ArticleId><ArticleId IdType="pubmed">36356052</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A. J.; et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021, 29, 463–476.E6. 10.1016/j.chom.2021.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L.; et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 2020, 183, 1024–1042.e21. 10.1016/j.cell.2020.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes C. O.; et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020, 588, 682–687. 10.1038/s41586-020-2852-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2852-1</ArticleId><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie K. M.; et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science 2021, 374, 472–478. 10.1126/science.abh2315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2315</ArticleId><ArticleId IdType="pmc">PMC9302186</ArticleId><ArticleId IdType="pubmed">34554826</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M.; et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science 2021, 373, 818.10.1126/science.abh1139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1139</ArticleId><ArticleId IdType="pmc">PMC8284396</ArticleId><ArticleId IdType="pubmed">34016740</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M.; et al. A broad and potent neutralization epitope in SARS-related coronaviruses. Proc. Natl. Acad. Sci. U. S. A. 2022, 119, e2205784119.10.1073/pnas.2205784119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2205784119</ArticleId><ArticleId IdType="pmc">PMC9304036</ArticleId><ArticleId IdType="pubmed">35767670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y.; et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022, 608, 593–602. 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jette C. A.; et al. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep. 2021, 36, 109760.10.1016/j.celrep.2021.109760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109760</ArticleId><ArticleId IdType="pmc">PMC8423902</ArticleId><ArticleId IdType="pubmed">34534459</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A. J.; et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe 2021, 29, 44–57.E9. 10.1016/j.chom.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y.-J.; et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 2022, 378, 619–627. 10.1126/science.adc9127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adc9127</ArticleId><ArticleId IdType="pubmed">36264829</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J.;et al.SARS-CoV-2 Antibodies Recognize 23 Distinct Epitopic Sites on the
Receptor Binding Domain. https://www.researchsquare.com/article/rs-2800118/v1 (2023.  preprint);10.21203/rs.3.rs-2800118/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-2800118/v1</ArticleId><ArticleId IdType="pmc">PMC10509263</ArticleId><ArticleId IdType="pubmed">37726484</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.-Y. A.; et al. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Nat. Commun. 2023, 14, 311.10.1038/s41467-023-35949-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-35949-8</ArticleId><ArticleId IdType="pmc">PMC9852238</ArticleId><ArticleId IdType="pubmed">36658148</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutalai R.; et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell 2022, 185, 2116–2131.E18. 10.1016/j.cell.2022.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.014</ArticleId><ArticleId IdType="pmc">PMC9120130</ArticleId><ArticleId IdType="pubmed">35662412</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A. J.; et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 2021, 12, 4196.10.1038/s41467-021-24435-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24435-8</ArticleId><ArticleId IdType="pmc">PMC8263750</ArticleId><ArticleId IdType="pubmed">34234131</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.; et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020, 584, 450–456. 10.1038/s41586-020-2571-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2571-7</ArticleId><ArticleId IdType="pubmed">32698192</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.; et al. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Sci. Transl. Med. 2022, 14, eabn6859.10.1126/scitranslmed.abn6859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn6859</ArticleId><ArticleId IdType="pmc">PMC9017343</ArticleId><ArticleId IdType="pubmed">35438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.; et al. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity 2020, 53, 1272–1280.E5. 10.1016/j.immuni.2020.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.10.023</ArticleId><ArticleId IdType="pmc">PMC7687367</ArticleId><ArticleId IdType="pubmed">33242394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M.; et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020, 368, 630–633. 10.1126/science.abb7269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7269</ArticleId><ArticleId IdType="pmc">PMC7164391</ArticleId><ArticleId IdType="pubmed">32245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H.; et al. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A. 2022, 119, e2204256119.10.1073/pnas.2204256119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2204256119</ArticleId><ArticleId IdType="pmc">PMC9407403</ArticleId><ArticleId IdType="pubmed">35972965</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y.; et al.Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2. bioRxiv 2023;10.1101/2023.01.19.524784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.19.524784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wec A. Z.; et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 2020, 369, 731–736. 10.1126/science.abc7424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc7424</ArticleId><ArticleId IdType="pmc">PMC7299279</ArticleId><ArticleId IdType="pubmed">32540900</ArticleId></ArticleIdList></Reference><Reference><Citation>He W.; et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nat. Immunol. 2022, 23, 960–970. 10.1038/s41590-022-01222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01222-1</ArticleId><ArticleId IdType="pmc">PMC10083051</ArticleId><ArticleId IdType="pubmed">35654851</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici M. A.; et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 2021, 597, 103–108. 10.1038/s41586-021-03817-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03817-4</ArticleId><ArticleId IdType="pmc">PMC9341430</ArticleId><ArticleId IdType="pubmed">34280951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y.; et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2022, 1–3. 10.1038/s41586-022-05644-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05644-7</ArticleId><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B.; et al. Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209. Cell Res. 2022, 32, 491–494. 10.1038/s41422-022-00638-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00638-6</ArticleId><ArticleId IdType="pmc">PMC8902274</ArticleId><ArticleId IdType="pubmed">35260792</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D.; et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 2021, 184, 4203–4219.E32. 10.1016/j.cell.2021.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.021</ArticleId><ArticleId IdType="pmc">PMC8232969</ArticleId><ArticleId IdType="pubmed">34242577</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss W. N.; et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Rep. Med. 2024, 5, 10166810.1016/j.xcrm.2024.101668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2024.101668</ArticleId><ArticleId IdType="pmc">PMC11384961</ArticleId><ArticleId IdType="pubmed">39094579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J.; et al. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. J. Med. Virol. 2023, 95, e28172.10.1002/jmv.28172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28172</ArticleId><ArticleId IdType="pmc">PMC9538210</ArticleId><ArticleId IdType="pubmed">36161303</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A. C.; et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 2021, 184, 5432–5447.E16. 10.1016/j.cell.2021.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.015</ArticleId><ArticleId IdType="pmc">PMC8440233</ArticleId><ArticleId IdType="pubmed">34619077</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A. A.; et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 2021, 371, 735–741. 10.1126/science.abf6840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6840</ArticleId><ArticleId IdType="pmc">PMC7928838</ArticleId><ArticleId IdType="pubmed">33436524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills R. A.; et al.Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology. bioRxiv 2023;10.1101/2023.02.24.529520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.24.529520</ArticleId><ArticleId IdType="pmc">PMC11329374</ArticleId><ArticleId IdType="pubmed">38710880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishwanath S.; et al. A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses. Nat. Biomed. Eng. 2023, 1–14. 10.1038/s41551-023-01094-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-023-01094-2</ArticleId><ArticleId IdType="pubmed">37749309</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J.; et al. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. J. Virol. 2022, 96, e00118–22. 10.1128/jvi.00118-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00118-22</ArticleId><ArticleId IdType="pmc">PMC9472618</ArticleId><ArticleId IdType="pubmed">35972290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser B. M.; et al. Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design. Cell Rep. Med. 2022, 3, 100834.10.1016/j.xcrm.2022.100834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100834</ArticleId><ArticleId IdType="pmc">PMC9663748</ArticleId><ArticleId IdType="pubmed">36423634</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnell G. W. Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. Front. Immunol. 2023, 14, 1.10.3389/fimmu.2023.1118523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1118523</ArticleId><ArticleId IdType="pmc">PMC9995963</ArticleId><ArticleId IdType="pubmed">36911730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W.-S.; Chen I-C.; Chen H.-C.; Lee Y.-C.; Wu S.-C. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Front. Immunol. 2021, 12, 1.10.3389/fimmu.2021.795741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.795741</ArticleId><ArticleId IdType="pmc">PMC8674692</ArticleId><ArticleId IdType="pubmed">34925381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser B. M.; et al. Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. Cell Rep. 2022, 38, 110561.10.1016/j.celrep.2022.110561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110561</ArticleId><ArticleId IdType="pmc">PMC8898741</ArticleId><ArticleId IdType="pubmed">35303475</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S.; et al. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Virol. J. 2022, 19, 2.10.1186/s12985-021-01737-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01737-3</ArticleId><ArticleId IdType="pmc">PMC8724645</ArticleId><ArticleId IdType="pubmed">34983583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B.; et al. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice. J. Med. Virol. 2022, 94, 3992–3997. 10.1002/jmv.27811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27811</ArticleId><ArticleId IdType="pmc">PMC9088529</ArticleId><ArticleId IdType="pubmed">35474319</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidenbacher P. A.; Kim P. S. Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope. Proc. Natl. Acad. Sci. U. S. A. 2019, 116, 9947–9952. 10.1073/pnas.1822062116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1822062116</ArticleId><ArticleId IdType="pmc">PMC6525525</ArticleId><ArticleId IdType="pubmed">31028143</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A.; et al.Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans. bioRxiv 2024;10.1101/2024.03.31.586409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.31.586409</ArticleId><ArticleId IdType="pubmed">39058596</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrell A. G.; et al. Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2. Viruses 2022, 14, 2061.10.3390/v14092061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14092061</ArticleId><ArticleId IdType="pmc">PMC9504593</ArticleId><ArticleId IdType="pubmed">36146867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi R.; et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 2020, 584, 120–124. 10.1038/s41586-020-2381-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2381-y</ArticleId><ArticleId IdType="pubmed">32454512</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D.; et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020, 583, 290–295. 10.1038/s41586-020-2349-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis D.; et al. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Front. Immunol. 2021, 12, 2605.10.3389/fimmu.2021.710263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.710263</ArticleId><ArticleId IdType="pmc">PMC8276696</ArticleId><ArticleId IdType="pubmed">34267764</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T. N.; et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 2020, 182, 1295–1310.E20. 10.1016/j.cell.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T. N.; et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 2021, 597, 97–102. 10.1038/s41586-021-03807-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03807-6</ArticleId><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro-Pérez L.; et al. Conformational characterization of the mammalian-expressed SARS-CoV-2 recombinant receptor binding domain, a COVID-19 vaccine. Biol. Res. 2023, 56, 22.10.1186/s40659-023-00434-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-023-00434-5</ArticleId><ArticleId IdType="pmc">PMC10164616</ArticleId><ArticleId IdType="pubmed">37150832</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatri R.; et al. Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. Protein J. 2022, 41, 457–467. 10.1007/s10930-022-10073-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10930-022-10073-6</ArticleId><ArticleId IdType="pmc">PMC9434506</ArticleId><ArticleId IdType="pubmed">36048314</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer P. J. M.; et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020, 369, 643–650. 10.1126/science.abc5902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5902</ArticleId><ArticleId IdType="pmc">PMC7299281</ArticleId><ArticleId IdType="pubmed">32540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullen G. R.; Fitzgerald M. G.; Hosking C. S. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 1986, 86, 83–87. 10.1016/0022-1759(86)90268-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(86)90268-1</ArticleId><ArticleId IdType="pubmed">3944471</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrock E. L.; et al. Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses. Science 2023, 380, eadc9498.10.1126/science.adc9498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adc9498</ArticleId><ArticleId IdType="pmc">PMC10273302</ArticleId><ArticleId IdType="pubmed">37023193</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A. C.; et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020, 181, 281–292.E6. 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott R. K.; Crotty S. Factors in B cell competition and immunodominance. Immunol. Rev. 2020, 296, 120–131. 10.1111/imr.12861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12861</ArticleId><ArticleId IdType="pmc">PMC7641103</ArticleId><ArticleId IdType="pubmed">32483855</ArticleId></ArticleIdList></Reference><Reference><Citation>Amitai A.; et al. Defining and Manipulating B Cell Immunodominance Hierarchies to Elicit Broadly Neutralizing Antibody Responses against Influenza Virus. Cell Syst. 2020, 11, 573–588.E9. 10.1016/j.cels.2020.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.09.005</ArticleId><ArticleId IdType="pmc">PMC7746579</ArticleId><ArticleId IdType="pubmed">33031741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirelli K. M.; et al. Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell 2019, 177, 1153–1171.E28. 10.1016/j.cell.2019.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.04.012</ArticleId><ArticleId IdType="pmc">PMC6619430</ArticleId><ArticleId IdType="pubmed">31080066</ArticleId></ArticleIdList></Reference><Reference><Citation>Havenar-Daughton C.; Lee J. H.; Crotty S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol. Rev. 2017, 275, 49–61. 10.1111/imr.12512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12512</ArticleId><ArticleId IdType="pubmed">28133798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y.; et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 2023, 23, 135–136. 10.1038/s41577-022-00825-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00825-x</ArticleId><ArticleId IdType="pmc">PMC9764299</ArticleId><ArticleId IdType="pubmed">36539526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.-M.; Cheng T.-L.; Roffler S. R. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano 2021, 15, 14022–14048. 10.1021/acsnano.1c05922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c05922</ArticleId><ArticleId IdType="pubmed">34469112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y.; et al. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano 2022, 16, 11769–11780. 10.1021/acsnano.2c04543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.2c04543</ArticleId><ArticleId IdType="pubmed">35758934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett N. R.; et al. Atomically accurate de novo design of single-domain antibodies. BioRxiv Prepr. Serv. Biol. 2024, 2024.03.14.585103.10.1101/2024.03.14.585103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.14.585103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett N. R.; et al. Improving de novo protein binder design with deep learning. Nat. Commun. 2023, 14, 2625.10.1038/s41467-023-38328-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38328-5</ArticleId><ArticleId IdType="pmc">PMC10163288</ArticleId><ArticleId IdType="pubmed">37149653</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L.; et al. Design of protein-binding proteins from the target structure alone. Nature 2022, 605, 551–560. 10.1038/s41586-022-04654-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04654-9</ArticleId><ArticleId IdType="pmc">PMC9117152</ArticleId><ArticleId IdType="pubmed">35332283</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuchowski A.; van Es T.; Palczuk N. C.; Davis F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 1977, 252, 3578–3581. 10.1016/S0021-9258(17)40291-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)40291-2</ArticleId><ArticleId IdType="pubmed">405385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun T. U. J.; Andersson A.-M. M. C.; Draper S. J.; Howarth M. Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination. ACS Nano 2018, 12, 8855–8866. 10.1021/acsnano.8b02805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b02805</ArticleId><ArticleId IdType="pmc">PMC6158681</ArticleId><ArticleId IdType="pubmed">30028591</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D.; et al. Vaccine design via antigen reorientation. Nat. Chem. Biol. 2024, 20, 1012.10.1038/s41589-023-01529-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-023-01529-6</ArticleId><ArticleId IdType="pmc">PMC11247139</ArticleId><ArticleId IdType="pubmed">38225471</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey S. J.; et al. Nanovaccines Displaying the Influenza Virus Hemagglutinin in an Inverted Orientation Elicit an Enhanced Stalk-Directed Antibody Response. Adv. Healthc. Mater. 2023, 12, e2202729.10.1002/adhm.202202729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202202729</ArticleId><ArticleId IdType="pmc">PMC10386890</ArticleId><ArticleId IdType="pubmed">36689343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.; et al. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines. Nat. Commun. 2024, 15, 5496.10.1038/s41467-024-49656-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-49656-5</ArticleId><ArticleId IdType="pmc">PMC11214633</ArticleId><ArticleId IdType="pubmed">38944664</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidenbacher P. A.-B.; et al. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nat. Commun. 2023, 14, 2149.10.1038/s41467-023-37417-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37417-9</ArticleId><ArticleId IdType="pmc">PMC10110616</ArticleId><ArticleId IdType="pubmed">37069151</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett D.; Kovaleva E.; Schatz P. J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. Publ. Protein Soc. 1999, 8, 921–929. 10.1110/ps.8.4.921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1110/ps.8.4.921</ArticleId><ArticleId IdType="pmc">PMC2144313</ArticleId><ArticleId IdType="pubmed">10211839</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford K. H. D.; et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 2020, 12, 513.10.3390/v12050513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12050513</ArticleId><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>